A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating ...

Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Mural Oncology in a research ...

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials ...

Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...

Morgan Stanley downgraded Mural Oncology (MURA) to Equal Weight from Overweight and removed the firm’s prior $13 price target after removing ...

Raymond James downgraded Mural Oncology (MURA) to Outperform from Strong Buy with a price target of $6, down from $18, after the company ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Mural Oncology plc (MURA), a pharmaceutical company focused on developing treatments for cancer, announced today that it will discontinue the development of its drug candidate nemvaleukin alfa for ...

Indio has a new mural that's meaning goes beyond creative art. Artist Patrick Barwinski created the "Desi Memorial Mural," in ...